Merck & Co.'s Keytruda, BioLineRx's Motixafortide Combine To Good Effect In Pancreatic Cancer
Keytruda Also Shown To Work With Eisai's Lenvima In Endometrial Cancer
BioLineRx's Phase IIa study of Keytruda/motixafortide/chemo showed improvements in overall and progression-free survival compared with historical data.
You may also be interested in...
Merck’s Keytruda Works With Lenvima In Renal Cancer, But Not With Yervoy In Lung Cancer
Merck’s PD-1 inhibitor combined with Lenvima offered benefit in RCC, but use with Bristol’s Yervoy in metastatic NSCLC showed no benefit compared to Keytruda monotherapy.
Interview: BioLineRx Pushes Ahead In Pancreatic Cancer
The Israeli group is confident that its CXCR4 antagonist has potential as a platform molecule for a range of cancers at various stages of disease.
Twin Presentations Position Merck, GSK PD-1 Inhibitors As Endometrial Cancer Rivals
Merck’s Keytruda may nevertheless have the stronger market position given its broader and stronger labeling in second-line endometrial cancer and strong position in women’s oncology overall.